| 12/06/25 | GSK | 11:00:00 | 12 Jun 2025 | | GSK | Director/PDMR Shareholding | GSK plc | PRN |
| 25/05/22 | GSK | 15:41:00 | 25 May 2022 | | GSK | Director/PDMR Shareholding | GSK plc | PRN |
| 01/12/21 | GSK | 11:05:00 | 1 Dec 2021 | | GSK | Total Voting Rights | GSK plc | PRN |
| 26/07/17 | | 12:00:00 | 26 Jul 2017 | | | Half-year Report | GlaxoSmithKline PLC | RNS |
| 25/07/17 | | 14:30:34 | 25 Jul 2017 | | | ViiV announces results from NEAT 022 study | GlaxoSmithKline PLC | RNS |
| 25/07/17 | | 14:30:24 | 25 Jul 2017 | | | ViiV announces positive results from DAWNING | GlaxoSmithKline PLC | RNS |
| 24/07/17 | | 10:02:13 | 24 Jul 2017 | | | LATTE-2 phII results presented at IAS in Paris | GlaxoSmithKline PLC | RNS |
| 21/07/17 | | 16:34:37 | 21 Jul 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 21/07/17 | | 16:30:19 | 21 Jul 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 21/07/17 | | 14:59:26 | 21 Jul 2017 | | | GSK submits EU filing for Relvar Ellipta extension | GlaxoSmithKline PLC | RNS |
| 21/07/17 | | 12:00:01 | 21 Jul 2017 | | | Directorate Change | GlaxoSmithKline PLC | RNS |
| 17/07/17 | | 19:08:13 | 17 Jul 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 17/07/17 | | 18:44:12 | 17 Jul 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 17/07/17 | | 18:37:32 | 17 Jul 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 17/07/17 | | 18:19:31 | 17 Jul 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 17/07/17 | | 17:53:01 | 17 Jul 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 17/07/17 | | 17:37:23 | 17 Jul 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 17/07/17 | | 15:20:58 | 17 Jul 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 14/07/17 | | 17:58:52 | 14 Jul 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 14/07/17 | | 17:46:58 | 14 Jul 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 14/07/17 | | 17:02:33 | 14 Jul 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 14/07/17 | | 12:57:54 | 14 Jul 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 12/07/17 | | 17:12:36 | 12 Jul 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 03/07/17 | | 11:05:26 | 3 Jul 2017 | | | Total Voting Rights | GlaxoSmithKline PLC | RNS |
| 28/06/17 | | 17:13:01 | 28 Jun 2017 | | | GSK announces US filing for mepo in EGPA | GlaxoSmithKline PLC | RNS |
| 27/06/17 | | 11:06:33 | 27 Jun 2017 | | | GSK starts phIII study on mepo for nasal polyps | GlaxoSmithKline PLC | RNS |
| 21/06/17 | | 15:35:53 | 21 Jun 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 21/06/17 | | 15:05:07 | 21 Jun 2017 | | | GSK presents Shingrix PhIII study results at ACIP | GlaxoSmithKline PLC | RNS |
| 19/06/17 | | 17:29:28 | 19 Jun 2017 | | | GSK confirms start date for Luke Miels | GlaxoSmithKline PLC | RNS |
| 12/06/17 | | 17:43:35 | 12 Jun 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 05/06/17 | | 18:23:08 | 5 Jun 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 02/06/17 | | 08:00:01 | 2 Jun 2017 | | | ViiV submits first 2-drug HIV regimen application | GlaxoSmithKline PLC | RNS |
| 01/06/17 | | 11:58:48 | 1 Jun 2017 | | | Total Voting Rights | GlaxoSmithKline PLC | RNS |
| 31/05/17 | | 17:25:48 | 31 May 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 22/05/17 | | 17:45:52 | 22 May 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 22/05/17 | | 17:40:03 | 22 May 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 22/05/17 | | 15:23:13 | 22 May 2017 | | | Ph3 MUSCA study presented at ATS | GlaxoSmithKline PLC | RNS |
| 18/05/17 | | 08:00:07 | 18 May 2017 | | | NEJM publication of PH3 study into Mepo in EGPA | GlaxoSmithKline PLC | RNS |
| 12/05/17 | | 17:26:40 | 12 May 2017 | | | Block listing Interim Review | GlaxoSmithKline PLC | RNS |
| 11/05/17 | | 18:29:18 | 11 May 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 10/05/17 | | 17:26:50 | 10 May 2017 | | | Headline Phase III results: Mepo in COPD | GlaxoSmithKline PLC | RNS |
| 05/05/17 | | 13:39:22 | 5 May 2017 | | | Rellvar Ellipta 2nd Salford Lung Study Results | GlaxoSmithKline PLC | RNS |
| 04/05/17 | | 19:10:56 | 4 May 2017 | | | Result of AGM | GlaxoSmithKline PLC | RNS |
| 02/05/17 | | 14:02:51 | 2 May 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 02/05/17 | | 11:02:52 | 2 May 2017 | | | Total Voting Rights | GlaxoSmithKline PLC | RNS |
| 27/04/17 | | 18:40:26 | 27 Apr 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 27/04/17 | | 17:53:01 | 27 Apr 2017 | | | Companies Act 2006 s430 (2B) Disclosure | GlaxoSmithKline PLC | RNS |
| 26/04/17 | | 18:25:29 | 26 Apr 2017 | | | Indenture 2004 - change of trustee | GlaxoSmithKline PLC | RNS |
| 26/04/17 | | 13:00:45 | 26 Apr 2017 | | | 1st Quarter Results | GlaxoSmithKline PLC | RNS |
| 25/04/17 | | 18:24:16 | 25 Apr 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
